346 Steps in the Right Direction: Asthma Clinical Trials

346 Steps in the Right Direction: Asthma Clinical Trials

Posted on August 15, 2012 by Barbara Cybart in Asthma Research

In the area of asthma clinical trials, Canada is being dwarfed by the United States (US) in sheer number of trials. According to clinicaltrials.gov in Canada, there are 346 on-going asthma clinical trials, whereas in the US there are 3439. Therefore, the US is running 993% more asthma clinical trials than Canada. However, the USA’s population is significantly greater than Canada, though this fact should not limit the Canadian health industry’s ambitions. Especially if relying solely on population demographics to judge how many asthma clinical trials should be run in Canada, then the US has a population of 314,077,124 people, while Canada has a population of 34,482,779. In Canada that means that there are 9,966 people per 1 clinical trial, however the US has 913,280 people per 1 clinical trial, meaning Canada has a greater frequency of clinical trials than the US.

One Canadian asthma clinical trial, “Should Non-Eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?” is being run by the Université de Montréal with the help of the University of Ottawa, the Laval University, the University of British Columbia and McGill University. The purpose of the is to determine whether inhaled corticosteroids (ICS) alone or in combination with long-acting beta-2 agonists are an effective treatment in non-eosinophilic asthmatic subjects, since the efficacy of ICS in asthmatic subjects showing no sputum eosinophils is a controversial subject. Upon conclusion, the study aims to determine whether or not non-eosinophilic asthmatic subjects respond to ICS and if they further benefit from the addition of a long-acting beta-2 agonist and whether. The results of the trial will indicate whether the assessment of airway inflammation should be performed in every asthmatic patient in order to prescribe the most appropriate treatment.[1]

Another asthma clinical trial, the “Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial” which began in January of 2003, reached completion in October 2008. The trial was sponsored by Pfizer, and assessed the usefulness and safety of inhaled insulin in diabetic with asthma. The trial was concluded successfully, demonstrating the increased safety of subcutaneous[2] human insulin use over inhaled human insulin through their results which can be accessed through this link: Study Results: A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma.[3]

The information gathered by clinical trials, such as the two above will help people manage their asthma more effectively and lead healthier lives. Therefore, the more asthma clinical trials are being run, the more opportunities that are being created to advance asthma treatment.

Discover Clinical Trials hope to add to this success in the asthma clinical trials, through our own asthma clinical trial being run by Dr. Gordon Sussman[4], an allergist of national renown and his team from Genetech.


[1] Should Non-Eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids? By Universite de Montreal. Accessed August 2, 2012. http://clinicaltrials.gov/show/NCT00509197

[2] Subcutaneous: being, living, used, or made under the skin<subcutaneous parasites> http://www.merriam-webster.com/medical/subcutaneous

[3] A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma. Accessed August 2, 2012. http://clinicaltrials.gov/ct2/show/results/NCT00139659

[4] Sussman Research Allergy Research for Patients in Toronto. Accessed August 2, 2012. http://sussmanresearch.com/clinical-trials/